Enhanced susceptibility of HLA-mediated ticlopidine-induced idiosyncratic hepatotoxicity by CYP2B6 polymorphism in Japanese

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 3, 2010, Pages 298-306

  Ariyoshi, Noritaka ^a,d   Iga, Yukako ^b   Hirata, Koji ^c   Sato, Yasunori ^d,e   Miura, Go ^a   Ishii, Itsuko ^b   Nagamori, Seiji ^f   Kitada, Mitsukazu ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Product Lifecycle Management Department   (Japan)

^d CHIBA UNIVERSITY HOSPITAL   (Japan)

^e Chan School of Public Health   (United States)

^f KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP2B6; Haplotype; HLA; Interethnic difference; Metabolic activation; Ticlopidine induced hepatotoxicity

Indexed keywords

CYTOCHROME P450 2B6; HLA A ANTIGEN; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; CYP2B6 PROTEIN, HUMAN; HLA ANTIGEN; N DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; EXON; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HLA SYSTEM; HUMAN; HUMAN CELL; INCIDENCE; INTRON; JAPANESE; LIVER TOXICITY; MAJOR CLINICAL STUDY; PREVALENCE; REPORTER GENE; SINGLE NUCLEOTIDE POLYMORPHISM; BIOTRANSFORMATION; CASE CONTROL STUDY; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; ENZYME ACTIVATION; ETHNOLOGY; GENETICS; GENOTYPE; JAPAN;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2B6; DRUG-INDUCED LIVER INJURY; ENZYME ACTIVATION; GENOTYPE; HAPLOTYPES; HLA ANTIGENS; HUMANS; JAPAN; OXIDOREDUCTASES, N-DEMETHYLATING; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; TICLOPIDINE;

EID: 77954279332     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.298     Document Type: Article

References (37)

1. Mallal, S., Phillips, E., Carosi, G., Molina, J. M., Workman, C., Tomazic, J. Jagel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., Hay, P., Nolan, D., Hughes, S., Hughes, A., Ryan, S., Fitch, N., Thorborn, D. and Benbow, A.: PREDICT-1 Study Team.: HLAB*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med., 358: 568-579 (2008).
2. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y. and Chen, Y. T.: Medical genetics: amarker for Stevens-Johnson syndrome. Nature, 428: 486 (2004).
3. Hung, S. I., Chung, W. H., Liou, L. B., Chu, C. C., Lin, M., Huang, H. P., Lin, Y. L., Lan, J. L., Yang, L. C., Hong, H. S., Chen, M. J., Lai, P. C., Wu, M. S., Chu, C. Y., Wang, K. H., Chen, C. H., Fann, C. S., Wu, J. Y. and Chen, Y. T.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA., 102: 4134-4139 (2005).
4. McTavish, D., Faulds, D. and Goa, K. L.: Ticlopidine: an update review of its pharmacology and therapeutic use in platelet dependent disorders. Drugs, 40: 238-259 (1990).
5. Mizushima, M., Iwata, N., Fujimoto, T. T., Ishikawa, K. and Fujimura, K.: Patient characteristics in ticlopidine hydrochloride-induced liver injury: case-control study. Hepatol. Res., 33: 234-240 (2005).
6. Cassidy, L. J., Schuster, B. G. and Halparin, L. S.: Probable ticlopidine-induced cholestatic hepatitis. Ann. Pharmacother., 29: 30-32 (1995).
7. Berent, R., Hinterholzer, G., Hoäbling, W., Auer, J., Haidenthaler, A. and Knoflach, P.: Cholestatic hepatitis as a rare side effect of therapy with ticlopidine. Z. Gastroenterol., 38: 587-591 (2000).
8. Skurnik, Y. D., Tcherniak, A., Edlan, K. and Sthoeger, Z.: Ticlopidine-induced cholestatic hepatitis. Ann. Pharmacother., 37: 371-375 (2003).
9. Dansette, P. M., Amar, C., Valadon, P., Pons, C., Beaune, P. H. and Mansuy, D.: Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation. Biochem. Pharmacol., 41: 553-360 (1991).
10. Loápez Garcia, M. P., Dansette, P. M., Valadon, P., Amar, C., Beaune, P. H., Guengerich, F. P. and Mansuy, D.: Human-liver cytochrome P-450 expressed in yeast as tools for reactivemetabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur. J. Biochem., 213: 223-232 (1993).
11. Lecoeur, S., Bonierbale, E., Challine, D., Gautier, J. C., Valadon, P., Dansette, P. M., Catinot, R., Ballet, F., Mansuy, D. and Beaune, P. H.: Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem. Res. Toxicol., 7: 434-442 (1994).
12. Bonierbale, E., Valadon, P., Pons, C., Desfosses, B., Dansette, P. M. and Mansuy, D.: Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds. Chem. Res. Toxicol., 12: 286-296 (1999).
13. Beaune, P., Dansette, P. M., Mansuy, D., Kiffel, L., Finck, M., Amar, C. Leroux, J. P. and Homberg, J. C.: Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc. Natl. Acad. Sci. USA., 84: 551-555 (1987).
14. Dalvie, D. K. and O'Connell, T. N.: Characterization of novel dihydrothienopyridinum and thienopyridinum metabolites of ticlopidine in vitro: role of peroxidases, cytochrome P450, and monoamine oxidases. Drug Metab. Dispos., 32: 49-57 (2004).
15. Clarke, T. A. and Waskell, L. A.: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos., 31: 53-59 (2003).
16. Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A. and Okazaki, O.: Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos., 38: 92-99 (2010).
17. Takikawa, H.: Lessons from ticlopidine-induced liver injury. Hepatol. Res., 33: 193-194 (2005).
18. Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., Shimizu, S., Masumoto, H. and Okutani, Y.: Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogemonic J., 8: 29-33 (2008).
19. Richter, T., Murdter, T. E., Heinkele, G., Pleiss, J., Tatzel, S., Schwab, M., Eichelbaum, M. and Zanger, U. M.: Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther., 308: 189-197 (2004).
20. Hagihara, K., Nishiya, Y., Kurihara, A., Kazui, M., Farid, N. A. and Ikeda, T.: Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab. Pharmacokinet., 23: 412-420 (2008).
21. Ariyoshi, N., Miyazaki, M., Toide, K., Sawamura, Y. and Kamataki, T.: A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation. Biochem. Biophys. Res. Commun., 281: 1256-1260 (2001).
22. Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics, 11: 399-415 (2001).
23. Lang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J. Pharmacol. Exp. Ther., 311: 34-43 (2004).
24. Hiratsuka, M., Hinai, Y., Konno, Y., Nozawa, H., Konno, S. and Mizugaki, M.: Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals. Drug Metab. Pharmacokin., 19: 155-158 (2004).
25. Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W. H., Eichelbaum, M., Schwab, M. and Zanger, U. M.: Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genom., 15: 861-873 (2005).
26. Zukunft, J., Lang, T., Richter, T., Hirsch-Ernst, K. I., Nussler, A. K., Klein, K., Schwab, M., Eichelbaum, M. and Zanger, U. M.: A natural CYP2B6 TATA box polymorphism (-82TaC) leading to enhanced transcriptional and relocation of the transcriptional start site. Mol. Pharmacol., 67: 1772-1782 (2005).
27. Hesse, L. M., He, P., Krishnaswamy, S., Hao, Q., Hogan, K., von Moltke, L. L., Greenblatt, D. J. and Court, M. H.: Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics, 14: 225-238 (2004).
28. Kawada, M., Nagamori, S., Aizaki, H., Fukaya, K., Niiya, M., Matsuura, T., Sujino, H., Hasumura, S., Yashida, H., Mizutani, S. and Ikenaga, H.: Massive culture of human liver cancer cells in a newly developed radial flow bioreactor system: ultrafine structure of functionally enhanced hepatocarcinoma cell lines. In Vitro Cell Dev. Biol., 34: 109-115 (1998).
29. Kobayashi, K., Yamanaka, Y., Iwazaki, N., Nakajo, I., Hosokawa, M., Negishi, M. and Chiba, K.: Identification of HMG-CoA inhibitors as activator for human, mouse and rat constitutive abdrostane receptor. Drug Metab. Dispos., 33: 924-929 (2005).
30. Kraslova, I., Muchova, L., Vitek, L., Novotny, A., Svestka, T. and Bruha, R.: Ticlopidine-induced cholestatic inflammatory hepatitis: new insights into pathogenetic mechanisms of drug-related hepatotoxicity. Eur. J. Inflamm., 4: 55-67 (2006).
31. Ishizaki, T., Sohn, D. R., Kobayashi, K., Chiba, K., Lee, K. H., Shin, S. G., Andersson, T., Regårdh, C. G., Lou, Y. C., Zhang, Y., Dahl, M. L. and Bertilsson, L.: Interethnic difference in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther. Drug Monit., 16: 214-215 (1994).
32. de Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A. and Goldstein, J. A.: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem., 269: 15419-15422 (1994).
33. Ha-Duong, N. T., Dijols, S., Macherey, A. C., Goldstein, J. A., Dansette, P. M. and Mansuy, D.: Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry, 40: 12112-12122 (2001).
34. Nakajima, M., Komagata, S., Fujiki, Y., Kanada, Y., Ebi, H., Itoh, K, Mukai, H., Yokoi, T. and Minami, H.: Genetic polymorphism of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet. Genomics, 17: 431-445 (2007).
35. Cho, J. Y., Lim, H. S., Chung, J. Y., Yu, K. S., Kim, J. R., Shin, S. G. and Jang, I. J.: Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab. Dispos., 32: 1341-1344 (2004).
36. Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E. and Sabatine, M. S.: Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 360: 354-362 (2009).
37. O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., Rozenman, Y., Michelson, A. D., Hautvast, R. W., Ver Lee, P. N., Close, S. L., Shen, L., Mega, J. L., Sabatine, M. S. and Wiviott, S. D.: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials. Lancet, 374: 989-997 (2009).